TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02290613

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (one to two tablets corresponding to one to two verum tablets)
Study: NCT02346526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Tests
Description: Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Standard CT scans will be carried out prior to treatment, week 9, and week 25.
Study: NCT00289744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TWINRIX™ ADULT
Description: 2 doses IM injection in primary study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix TM
Description: If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix TM
Description: If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
Study: NCT03394989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 100/50 µg
Description: Test Arm: Dry powder inhaler

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT02346526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FACBC PET/MRI in a subset of participants
Description: Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride
Description: Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone scan
Description: Standard bone scans will be carried out prior to treatment, week 9, and week 25.
Study: NCT01840826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RED-D Care Management
Description: The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
Study: NCT03447249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659/TEZ/IVA
Description: Participants received VX-659/TEZ/IVA orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
Study: NCT03433586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: 81mg of aspirin to be taken daily for 10-14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
Study: NCT04578392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high ligation of ileocolic artery
Description: Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high ligation of ileocolic artery
Description: Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesenteric sparing
Description: Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesenteric sparing
Description: Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
Study: NCT00925210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sequential pEBUS - ENB
Description: Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected.
Study: NCT03380234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Worksheets
Description: Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whatsapp messages
Description: A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change \[15\]. They can then forward selected messages to other members of their household, especially smokers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online quizzes
Description: At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.

Intervention type: OTHER
Group type: OTHER
Intervention: Leaflet
Description: A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
Study: NCT01147081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEGRIVAC
Description: 126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
Study: NCT01506050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine ODT 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine ODT 5 mg
Study: NCT02133404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT04674839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-20
Description: fermented soymilk product

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: No active ingredient
Study: NCT00680290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise x 8 weeks
Study: NCT03136952

Intervention type: DEVICE
Intervention: NIRS frontal and occipital
Description: NIRS frontal and occipital on pediatric population during general anesthesia
Study: NCT03287752

Intervention type: DEVICE
Intervention: BASKA MASK
Description: Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
Study: NCT02133404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01407198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Orally, daily 200 - 400 mg BID
Study: NCT03287752

Intervention type: DEVICE
Intervention: Endotracheal tube
Description: Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
Study: NCT04185311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00964158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine GSK2340272A
Description: Two primary intramuscular (IM) injections and a booster IM injection
Study: NCT04185311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given intratumorally
Study: NCT00419276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory continuous femoral nerve block for 100 hours
Description: Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
Study: NCT03083821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baraclude
Description: Specified dose on specified day
Study: NCT04043936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification Intervention for Help-Seeking Stigma
Description: Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo Cognitive Bias Modification (CBM-Placebo)
Description: Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Psychoeducation
Description: Material presented with information on mental health literacy, mental health stigma, \& treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
Study: NCT03394989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Description: Comparator Arm: Dry powder inhaler
Study: NCT00985647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine (3TC)
Description: 3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine (3TC)
Description: 3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days.
Study: NCT03822364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-1
Description: Inhaled apomorphine via Staccato aerosol, Dose 1
Study: NCT00518050

Intervention type: BEHAVIORAL
Intervention: Focus group
Description: Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~* Screening, skin self-examination, sun protection, and other cancer preventive practices;~* Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~* Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment

Intervention type: BEHAVIORAL
Intervention: Survey
Description: History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
Study: NCT03009461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
Study: NCT00565656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEVACIZUMAB
Description: Administration of Bevacizumab
Study: NCT02786940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiophone
Description: Remote live monitoring for 15 days for detection or exclusion of arrhythmias

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiophone
Description: Remote live monitoring for 15 days for detection or exclusion of arrhythmias
Study: NCT00989976

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: normal sleep times
Description: 8.5 h bedtimes
Study: NCT01368666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perceval S Valve Prosthesis
Description: Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
Study: NCT00989976

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: bedtime restriction
Description: 4.5 h restricted bedtimes
Study: NCT02374125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis
Description: Applied only around teres major muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger Point Pressure Release
Description: Applied only in teres major muscle trigger points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized physiotherapy
Description: Exercises, TENS and cryotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized physiotherapy
Description: Exercises, TENS and cryotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized physiotherapy
Description: Exercises, TENS and cryotherapy
Study: NCT02882763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parents As Teachers (PAT)
Description: A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
Study: NCT04744636

Intervention type: DRUG
Group type: OTHER
Intervention: Other
Description: Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR.

Intervention type: DRUG
Group type: OTHER
Intervention: Other
Description: Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR.

Intervention type: DRUG
Group type: OTHER
Intervention: Other
Description: Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR.

Intervention type: DRUG
Group type: OTHER
Intervention: Other
Description: Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0).~The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP):~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR.
Study: NCT01940510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5424802
Description: Single dose without (Day 1) and with (Day 17) co-administration of rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: Multiple doses Days 8-16 and Days 17-20
Study: NCT02797691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CaCBT
Description: Culturally Adapted Cognitive Behaviour Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication/ Psychotherapy
Description: Medication/ Psychotherapy used as usual
Study: NCT04846335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hcl
Description: tablets of DOXY hydrocloride (Bassado)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets of placebo
Study: NCT01407198

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
Study: NCT02517450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an adventure-based training programme
Description: The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: a placebo control programme
Description: Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
Study: NCT02873078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive behavior therapy
Description: The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
Study: NCT00677794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clear fluids
Description: Clear fluids only after lunch.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picosalax
Description: Two sachets the evening prior to Video Capsule Endoscopy (VCE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
Study: NCT03358030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 416858
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 416858
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 416858
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT02116179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Intervention
Description: Participants will be randomly assigned, with a baseline and 3 month follow up assessments
Study: NCT03086161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual
Description: Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
Study: NCT02273921

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: EEG recording
Description: EEG is recorded once for each participant
Study: NCT01298336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500 mg twice a day seven days a week
Study: NCT02797691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication/ Psychotherapy
Description: Medication/ Psychotherapy used as usual
Study: NCT01298336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg per day seven days a week